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Background
Didanosine is a potent nucleoside reverse transcriptase
inhibitor used for HIV infection treatment. A once daily
administration of chewable/dispersible didanosine tab-
lets (Videx®) was available for children in Burkina Faso
but few pharmacokinetic data were reported with these
galenic form and administration scheme. This study is
part of a phase II trial on once-a-day pediatric HAART. The
objectives were to describe didanosine pharmacokinetics
and to establish relationships between doses, plasma con-
centrations and treatment efficacy in children.
Methods
Didanosine concentrations were measured in 40 children
after 2 weeks and in 9 children after 2 to 5 months of dida-
nosine lamivudine efavirenz combination. A total of 166
didanosine plasma samples were measured using an
HPLC assay with detection by UV absorbance. A popula-
tion pharmacokinetic model was developed with NON-
MEM. The link between maximal concentration (Cmax),
area under the curve (AUC) and the decrease in HIV-1
RNA levels after 12 months of treatment was evaluated.
The threshold AUC and Cmax improving efficacy were
determined and an optimized dosing schedule was simu-
lated.
Results
Didanosine pharmacokinetics was best described by a
one-compartment model with first order absorption and
elimination. Mean population pharmacokinetic estimates
with the corresponding inter-subject variabilities (%)
were: apparent elimination clearance CL/F = 146 L/h
(90%) and apparent volume of distribution V/F = 356 L
(122%). CL/F and V/F were increased, probably due to a
lower bioavailability with tablets than with pediatric pow-
der. Clearance increased with body surface area. The
decrease in viral load after 12 months of treatment was
significantly correlated with didanosine AUC and Cmax (p≤ 0.02) during the first weeks of treatment. An AUC > 0.85
mg/l.h was significantly linked to better viral load
decrease (3 vs. 2.4 log10 copies/ml, p < 0.03) and higher
percentage of children with undetectable viral load after
one year of treatment (95% vs. 68%, p = 0.056). Four chil-
dren developed viral resistances to didanosine before one
year of treatment, all of them had an AUC < 0.85 mg/L.h.
A Cmax > 0.4 mg/L was also correlated to a better viral load
from Fifth Dominique Dormont International Conference. Mother-to-child transmitted viral diseases: from transmission to children care
Paris, France. 26–28 March 2009
Published: 22 July 2009
Retrovirology 2009, 6(Suppl 1):P20 doi:10.1186/1742-4690-6-S1-P20
<supplement> <title> <p>Fifth Dominique Dormont International Conference. Host-Pathogen Interactions in Chronic Infections</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S1-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1742-4690-6-S1-info.pdf</url> </supplement>
This abstract is available from: http://www.retrovirology.com/content/6/S1/P20
© 2009 Hirt et al; licensee BioMed Central Ltd. Page 1 of 2
(page number not for citation purposes)
Retrovirology 2009, 6(Suppl 1):P20 http://www.retrovirology.com/content/6/S1/P20Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
decrease and to the absence of viral resistance to didanos-
ine.
Conclusion
A 360 mg/m2 ddI dose administered as tablets should be
a more appropriate dose to improve efficacy than 240 mg/
m2 in these children. However data on adverse events with
this dosage are missing.Page 2 of 2
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